Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

Opinion
Video

Sai-Hong Ou, MD, PhD, discusses the challenging management of patients EGFR-mutant non-small cell lung cancer who develop resistance to EGFR tyrosine kinase inhibitors, emphasizing the importance of understanding the resistance mechanism to tailor treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      4 experts in this video
      Patient Education and IRR Prophylaxis in Practice With Amivantamab/Lazertinib
      4 experts in this video
      From Trial to Practice: Integrating Amivantamab/Lazertinib in Advanced NSCLC
      Looking Ahead in HER2+ mBC: Unmet Needs, Future Perspectives and Highlights From ASCO 2025
      Looking Ahead in HER2+ mBC: Unmet Needs, Future Perspectives and Highlights From ASCO 2025
      Expert Insights: Later-Line Treatment Strategies for HER2+ Metastatic Breast Cancer
      Expert Insights: Later-Line Treatment Strategies for HER2+ Metastatic Breast Cancer
      Tucatinib Triplet Therapy: Efficacy, Safety and Clinical Decision-Making
      Tucatinib Triplet Therapy: Efficacy, Safety and Clinical Decision-Making
      Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
      Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
      Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
      Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
      According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
      Advances in NSCLC Bring Excitement in the Lung Space
      Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
      Taletrectinib Shows Positive Efficacy and Toxicity in ROS1+ NSCLC
      “It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
      Taletrectinib Is Suitable for First- and Second-Line ROS1+ NSCLC
      Related Content
      The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

      FDA OKs NGS Test for Tumor Profiling and as CDx for Sunvozertinib in NSCLC

      Roman Fabbricatore
      July 7th 2025
      Article

      The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

      Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

      Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

      Stephen V. Liu, MD;Joshua K. Sabari, MD
      June 23rd 2025
      Podcast

      Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

      The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

      MARIPOSA OS Results Are Significant for EGFR+ NSCLC

      ONCOLOGY Staff
      July 2nd 2025
      Article

      The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

      Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      June 16th 2025
      Podcast

      Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.

      Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC Therapies

      Tim Cortese
      June 25th 2025
      Article

      Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.

      AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

      The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

      Puneet Modgil, MD
      June 24th 2025
      Article

      AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.